CRISPR Technology Market By Product (Enzymes, Kits and Reagents, Guide RNA, and Others (Antibodies, Vectors, and Design Tools)), By Application (Biomedical, Agricultural, Industrial, and Others), By End User (Pharmaceutical Companies and Biotechnology Companies, Academics and Government Research Institutes, and Other (CRO)), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI386720 | Publish Date: May 2024 | No. of Pages: 180

Global CRISPR Technology Market Market Companies

  • Cellecta, Inc.
  • GeneCopoeia, Inc.
  • GenScript
  • Horizon Discovery Group
  • Integrated DNA Technologies
  • Merck KGaA
  • New England Biolabs
  • Origene Technologies, Inc.
  • Thermo Fisher Scientific
  • Agilent Technologies

Recent News:

  • The FDA designates EBT-101 as Fast Track in August 2023. This designation supports Excision's efforts to quickly develop potentially curative medicines for major unmet medical needs and emphasizes how important it is to discover a cure for those living with HIV.Using an adeno-associated virus (AAV) to deliver CRISPR-Cas9 and dual guide RNAs to target three sites in the HIV genome, make two cuts in integrated retroviral DNA that remove a significant portion of the HIV genome, and ultimately stop viral escape and reproduction, EBT-101 is a potentially curative one-time treatment.
  • Casgevy, the first CRISPR-based treatment for sickle cell anemia supported by Vertex Pharmaceuticals, received FDA approval in December 2023. The United Kingdom was the first nation to authorize Casgevy. Numerous scientists and interested parties responded enthusiastically to this discovery, including Emmanuelle Charpentier, PhD, and Jennifer Doudna, PhD, the recipients of the CRISPR gene editing Nobel prize.